Cycc current stock price

CYCC - Significant Upside With Recent Multi-Million ...

CYCC Stock News and Price / Cyclacel Pharmaceuticals, Inc ... CYCC / Cyclacel Pharmaceuticals, Inc. 10-K - Annual Report - 10-K. 03-05 sec.gov Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO … CYCC Stock Analysis: Price, Forecast, and News CYCC Stock Analysis Overview . What this means: Cyclacel Pharmaceuti (CYCC) gets an Overall Rank of 57, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. David Dreman Guru Analysis of Cyclacel Pharmaceuticals ... Unfortunately, we do not have sufficient data available on CYCC at this time. This methodology would utilize four separate criteria to determine if CYCC is a contrarian stock. In order to eliminate weak companies we have stipulated that the stock should pass at least two of the following four major criteria in order to receive "Some Interest".

Cyclacel Pharmaceuticals Earnings Release Date - CYCC ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, 50 Day Moving Avg. 0.58; PE Ratio 0; Shares Outstanding 17.20M; Market Cap 6.21 M. 10 Mar 2020 Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company announcements to find out. Current Price: $0.37. View today's stock price, news and analysis for Cyclacel Pharmaceuticals Inc. ( CYCC). Barron's 25.12%. Current Vol65 Day Avg No news for CYCC. Aug 31  Current, Vs Industry, Vs History. 3-Year Average Share Buyback Ratio, -56.5. Valuation & Return. Current, Vs Industry, Vs History. Price-to-Tangible-Book, 0.71 . Upgrade to unlock premium data. File Date, Form, Security, Prev Shares, Current Shares, Change (Percent), Ownership ( 

Stock Comparison: Compare Cyclacel Pharmaceuticals, Inc ...

CYCC Stock Quote - Cyclacel Pharmaceuticals, Inc. Common ... Mar 27, 2020 · Stock quote for Cyclacel Pharmaceuticals, Inc. Common Stock Common Stock (CYCC) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. CYCC: Dividend Date & History for Cyclacel Pharmaceuticals Inc Gain insights on investing and current trends from the leading fund managers and industry experts. Cyclacel Pharmaceuticals Inc CYCC Dividend Yield & Stock Price History Download Historical Dividend Data for CYCC in .XLS Dividend Payout History. CYCC CYCC | Stock Snapshot - Fidelity Apr 03, 2020 · Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares. Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. CYCC: Cyclacel Pharmaceuticals Inc - Stock Price ... - CNBC

See Cyclacel Pharmaceuticals, Inc. (CYCC) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Cyclacel Pharmaceuticals, Inc. Common Stock (CYCC) Stock ...

Cyclacel Pharmaceuticals, Inc. (CYCC) Analyst Ratings ...

What is Cyclacel Pharmaceuticals's current dividend yield, its reliability and sustainability? Dividend Yield vs Market Notable Dividend : Unable to evaluate CYCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

Introducing Cyclacel Pharmaceuticals (NASDAQ:CYCC), The Stock That Tanked 92% Simply Wall St.-17.00% Dec-09-19 07:00AM Cyclacels CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias GlobeNewswire +26.05%